PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT: A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

Autor:	C. Graham, I. Gilloteau, M. Salibe, P.M. Bianculli, I. Peirano
Rok vydání:	2018
Předmět:	medicine.medical_specialty business.industry Health Policy Moderate to severe psoriasis Public Health Environmental and Occupational Health Medicine Secukinumab Biologic treatment business Dermatology
Zdroj:	Value in Health. 21:S428
ISSN:	1098-3015
DOI:	10.1016/j.jval.2018.09.2533
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9054f606ed96bfb93f36ef8ee45c6837 https://doi.org/10.1016/j.jval.2018.09.2533 Zobrazit plný text záznamu Full Text from ScienceDirect